Q2 2022 Earnings Estimate for AVROBIO, Inc. Issued By Wedbush (NASDAQ:AVRO)

AVROBIO, Inc. (NASDAQ:AVROGet Rating) – Wedbush increased their Q2 2022 earnings per share estimates for AVROBIO in a research report issued on Tuesday, May 10th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.30) for the quarter, up from their prior estimate of ($0.48). Wedbush also issued estimates for AVROBIO’s Q3 2022 earnings at ($0.30) EPS, Q4 2022 earnings at ($0.30) EPS, FY2022 earnings at ($1.41) EPS, FY2023 earnings at ($1.05) EPS, FY2024 earnings at ($0.76) EPS and FY2025 earnings at ($0.58) EPS.

AVROBIO (NASDAQ:AVROGet Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.10).

Other equities research analysts also recently issued research reports about the company. Barclays dropped their target price on AVROBIO from $6.00 to $4.00 in a research report on Wednesday. Zacks Investment Research downgraded AVROBIO from a “buy” rating to a “hold” rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $6.86.

NASDAQ:AVRO opened at $0.78 on Friday. The company has a market cap of $34.09 million, a P/E ratio of -0.28 and a beta of 1.73. The stock’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $2.56. AVROBIO has a 1 year low of $0.75 and a 1 year high of $11.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.27 and a quick ratio of 10.27.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its position in AVROBIO by 9.6% in the 1st quarter. BlackRock Inc. now owns 3,788,727 shares of the company’s stock worth $5,000,000 after buying an additional 332,639 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of AVROBIO by 219.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,381,758 shares of the company’s stock worth $5,319,000 after acquiring an additional 949,620 shares in the last quarter. Deep Track Capital LP bought a new stake in AVROBIO in the fourth quarter worth $4,043,000. Acadian Asset Management LLC lifted its stake in AVROBIO by 161.8% in the first quarter. Acadian Asset Management LLC now owns 913,457 shares of the company’s stock worth $1,204,000 after purchasing an additional 564,504 shares during the last quarter. Finally, BioImpact Capital LLC bought a new stake in AVROBIO in the third quarter worth $4,809,000. Hedge funds and other institutional investors own 63.92% of the company’s stock.

AVROBIO Company Profile (Get Rating)

AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.

Further Reading

Earnings History and Estimates for AVROBIO (NASDAQ:AVRO)

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.